Portage Biotech Inc (NAS:PRTG)
$ 6 3.1097 (115.16%) Market Cap: 6.29 Mil Enterprise Value: 1.31 Mil PE Ratio: 0 PB Ratio: 1.48 GF Score: 35/100

Portage Biotech Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 14, 2023 / 06:00PM GMT
Release Date Price: $59.5 (-2.78%)
Matt Biegler
Oppenheimer & Co. Inc. - Analyst

Hey, everyone. Thanks for joining the OpCo Healthcare Conference. My name's Matt Biegler. If you don't know me, I'm a covering analyst.

Very pleased to introduce one of our next covered companies, which is Portage. They are working on a diverse set of immunomodulatory agents for cancer. Here to tell us more is CEO, Ian Walters. So Ian, if you want to run through the deck, it'd be great.

Ian Walters
Portage Biotech Inc. - Chairman & CEO

Thanks, Matt. Thanks very much for having us today. For those of you who are not familiar with Portage, we are an immuno-oncology company, and we have four clinical-stage assets that I'll be telling you about shortly.

With these assets, they're really designed to be in robust clinical trials that will show human proof of concept, and we have multiple different catalysts within the next two years. This is being led by a team from BMS that helped develop the leading drugs in that area.

And we also have what we refer to as a cost-effective business

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot